



MISSISSIPPI DIVISION OF  
**MEDICAID**

**MISSISSIPPI DIVISION OF MEDICAID**  
**Pharmacy & Therapeutics Committee Meeting**

Woolfolk Building  
Conference Center East, Room 145  
Jackson, MS 39201-1399

**May 8, 2018**  
**10:00am to 5:00pm**

**MINUTES**

**Committee Members Present:**

Jeffrey A. Ali, M.D., M.Sc.  
John Cook, M.D.  
Logan Davis, Pharm.D., MBA  
Naznin Dixit, M.D.  
D. Stanley Hartness, M.D.  
Jason Parham, M.D.  
Spencer Sullivan, MD  
Geri Lee Weiland, M.D.  
Wilma Wilbanks, R.Ph

**Committee Members Not Present:**

Steven V. Dancer, R.Ph  
Brent Lindley, PharmD  
Deborah Minor, Pharm.D.

**Division of Medicaid Staff Present:**

Terri Kirby, B.S.Pharm., R.Ph., Pharmacy Director  
Cindy Noble, Pharm.D., MPH, Pharmacist III  
Drew Snyder, J.D., Executive Director  
Dorthy Young, Ph.D., Deputy Director of Health  
Services  
Chris A. Yount, MA, PMP, Staff Officer III

**Contract Staff/CHC Staff Present:**

Chad Bissell, Pharm.D., MBA  
Sarah Boydston, Pharm.D.  
Paige Clayton, Pharm.D.  
Jacqueline Hedlund, M.D., MS  
Shannon Hardwick, RPh

**Other Contract Staff Present:**

Ben Banahan, Ph.D. UM School of Pharmacy  
Karen Powell, Pharm.D., Conduent  
Lew Ann Snow, R.N., Conduent

Mississippi Pharmacy & Therapeutics Committee Meeting Minutes  
May 8, 2018

**Committee Attendance for SFY 2018**

	AUG 2017	NOV 2017	FEB 2018	MAY 2018	AUG 2018
Ali	x		x	x	
Cook		x		x	
Dancer			x		
Davis			x	x	
Dixit				x	
Hartness	x	x	x	x	
Lindley	x				
Minor	x	x	x		
Parham	x	x	x	x	
Sullivan	x	x	x	x	
Weiland		x		x	
Wilbanks	x	x	x	x	

DRAFT

## **I. Call to Order**

Ms. Wilma Wilbanks, Chairperson, called the meeting to order at 10:01 a.m.

## **II. Introductions**

Ms. Terri Kirby, Mississippi Division of Medicaid (DOM) Pharmacy Director, welcomed the Pharmacy & Therapeutics (P&T) Committee and all guests in the audience.

She introduced Change Healthcare, DOM's Preferred Drug List (PDL) and Supplemental Rebate (SR) vendor. All parties seated at the table introduced themselves and gave a brief statement about their professional credentials and affiliations.

Ms. Kirby recognized DOM contractors in the audience, including Dr. Karen Powell and Lew Ann Snow from Conduent, and Dr. Ben Banahan from the University of the Mississippi School of Pharmacy's MS-DUR Program and Change Healthcare (CHC) contractors, Dr. Paige Clayton, Dr. Sarah Boydston, Shannon Hardwick, RPh, Deirdre McCormick, Director, Business Development, Mary Dube, RN, Director, Operations, Morinee Terry, Sr. Human Resources Business Partner, Kerri Koski, Regional Pharmacy Director.

## **III. Administrative Matters**

Ms. Kirby reminded guests that if they did not sign the sign-in sheet prior to entering the room, to please do so. She stated that copies of the agenda and the public comment guidelines are available at the sign-in table. She stated that there is a separate sign in sheet for advocates and reminded guests that advocate presenters are limited to 5 minutes of general comment about a disease, not specific to a drug. She noted that industry presenters must provide their full name, drug name, identification, and company affiliation when signing in. She stated that industry presenters are allowed 3 minutes per drug and that no handouts are permitted. Presenters are requested to sign in at least 10 minutes prior to start of meeting.

Ms. Kirby stated that any documents used in the meeting that are not marked confidential and proprietary will be posted on DOM's website ([www.medicaid.ms.gov](http://www.medicaid.ms.gov)) after the meeting.

Ms. Kirby reviewed policies related to food and drink, cell phones and pagers, laptop usage, discussions in the hallways, and emergency procedures for the building.

Ms. Kirby stated that DOM aggressively pursues supplemental rebates. Mississippi is part of the Sovereign States Drug Consortium (SSDC) pool.

Ms. Kirby reviewed the voting procedure and reminded the Committee that, in accordance with the Mississippi Open Meetings Act, the minutes reflect each person's vote. She requested that the Chair announce the recommendation, motions, and the names of committee members making motions. The minutes for each P&T Committee meeting are posted to the DOM website ([www.medicaid.ms.gov](http://www.medicaid.ms.gov)) within 30 days of the meeting. The meeting minutes will be posted no later than June 7, 2018. Decisions will be announced no later than June 1, 2018 on the DOM website.

Ms. Kirby stated that the P&T Committee works in an advisory capacity and that DOM is responsible for final decisions related to the PDL. She reviewed the meeting process. She stated that DOM takes into account recommendations from both the P&T Committee and the clinical contractor before making a final decision. She stated that the PDL is completely updated once per year; quarterly updates are implemented throughout the year.

Ms. Kirby reviewed Committee policies and procedures. She requested that Committee members complete their travel vouchers and reviewed the contents of the folders provided to each Committee member.

#### **IV. Approval of February 13, 2018 Meeting Minutes**

Ms. Wilbanks asked for additions or corrections to the minutes from the February 13, 2018 meeting. There were no further additions or corrections. The minutes stand approved.

#### **V. PDL Compliance/Generic Percent Report Updates**

Dr. Clayton provided an explanation of the PDL Compliance and Generic Percent reports.

- A.** Dr. Clayton reviewed the PDL Compliance Report; overall compliance for Q1 2018 was 97.9%.
- B.** Dr. Clayton reviewed the Generic Percent Report; overall generic utilization for Q1 2018 was 88.5%.

#### **VI. Drug Class Announcements**

Dr. Bissell reviewed the meeting format.

#### **VII. Public Comments**

Nick Casale from Indivior spoke in favor of Sublocade.  
Timothy Birner from Alkemes spoke in favor of Vivitrol.  
Courtney Walker from Novo Nordisk spoke in favor of Ozempic.

#### **VIII. New Therapeutic Class Reviews**

##### **A. Antivirals (Oral)**

CHC recommended that the following list be approved. A clinical discussion followed. Dr. Weiland moved to accept the recommendation. Dr. Parham seconded. Votes were taken, and the motion was carried by unanimous approval. The approved category is below.

PREFERRED AGENTS	NON-PREFERRED AGENTS
<b>ANTI-CYTOMEGALOVIRUS AGENTS</b>	
valganciclovir tablets	PREVYMIS (letermovir) VALCYTE (valganciclovir) valganciclovir solution

### B. Opiate Dependence Treatments

CHC recommended that the following list be approved. A clinical discussion followed. Dr. Sullivan moved to accept the recommendation. Dr. Davis seconded. Votes were taken, and the motion was carried by unanimous approval. The approved category is below.

PREFERRED AGENTS	NON-PREFERRED AGENTS
<b>DEPENDENCE</b>	
naltrexone tablets SUBOXONE FILM (buprenorphine/naloxone)	buprenorphine tablets buprenorphine/naloxone tablets BUNAVAIL (buprenorphine/naloxone) PROBUPHINE (buprenorphine) SUBLOCADE (buprenorphine) VIVITROL (naltrexone) ZUBSOLV (buprenorphine/naloxone)

## IX. New Drug/New Generic Reviews

### A. Solosec

CHC recommended that Solosec be made Non-Preferred in the Antibiotics, GI category. Dr. Weiland moved to accept the recommendation. Dr. Hartness seconded. Votes were taken, and the motion was carried by unanimous approval. The approved category is below.

PREFERRED AGENTS	NON-PREFERRED AGENTS
ALINIA (nitazoxanide) metronidazole neomycin tinidazole	DIFICID (fidaxomicin) FLAGYL (metronidazole) FLAGYL ER (metronidazole) paromomycin SOLOSEC (secnidazole) TINDAMAX (tinidazole) VANCOCIN (vancomycin) vancomycin XIFAXAN (rifaximin)

## B. Biktarvy

CHC recommended that Biktarvy be made Preferred in the Antiretrovirals category. Dr. Parham moved to accept the recommendation. Dr. Weiland seconded. Votes were taken, and the motion was carried by unanimous approval. The approved category is below.

PREFERRED AGENTS	NON-PREFERRED AGENTS
<b>COMBINATION PRODUCTS – NUCLEOSIDE &amp; NUCLEOTIDE ANALOGS &amp; INTEGRASE INHIBITORS</b>	
BIKTARVY (bictegravir/emtricitabine/tenofovir) GENVOYA (elvitegravir/cobicistat/emtricitabine/tenofovir)	STRIBILD (elvitegravir/cobicistat/emtricitabine/tenofovir) TRIUMEQ (abacavir/lamivudine/ dolutegravir)

## C. Ozempic

CHC recommended that Ozempic be made Non-Preferred in the Hypoglycemics, Incretin Mimetics/Enhancers category. Dr. Sullivan moved to accept the recommendation. Dr. Hartness seconded. Votes were taken, and the motion was carried by unanimous approval. The approved category is below.

PREFERRED AGENTS	NON-PREFERRED AGENTS
BYDUREON (exenatide) VICTOZA (liraglutide)	ADLYXIN (lixisenatide) BYDUREON BCISE (exenatide) BYETTA (exenatide) OZEMPIC (semaglutide) SOLIQUA (insulin glargine/lixisenatide) SYMLIN (pramlintide) TRULICITY (dulaglutide) XULTOPHY (insulin degludec/ liraglutide)

## D. Admelog

CHC recommended that Admelog be made Non-Preferred in the Hypoglycemics, Insulins and Related Agents category. Dr. Hartness moved to accept the recommendation. Dr. Ali seconded. Votes were taken, and the motion was carried by unanimous approval. The approved category is below.

PREFERRED AGENTS	NON-PREFERRED AGENTS
HUMALOG VIAL (insulin lispro) HUMALOG MIX VIAL (insulin lispro/ lispro protamine) HUMULIN VIAL (insulin) LANTUS SOLOSTAR & VIAL (insulin glargine) LEVEMIR FLEXPEN & VIAL (insulin detemir) NOVOLOG FLEXPEN & VIAL (insulin aspart) NOVOLOG MIX FLEXPEN & VIAL (insulin aspart/ aspart protamine)	AFREZZA (insulin) ADMELOG (insulin lispro) APIDRA (insulin glulisine) BASAGLAR (insulin glargine) FIASP (insulin aspart) HUMALOG JR (insulin lispro) HUMALOG KWIKPEN (insulin lispro) HUMALOG MIX KWIKPEN (insulin lispro/ lispro protamine)

PREFERRED AGENTS	NON-PREFERRED AGENTS
	HUMULIN KWIKPEN (insulin) NOVOLIN FLEXPEN (insulin) NOVOLIN VIAL (insulin) TOUJEO (insulin glargine) TRESIBA (insulin degludec)

### E. Steglatro, Segluromet and Steglujan

CHC recommended that Steglatro, Segluromet and Steglujan all be made Non-Preferred in their respective Hypoglycemics sub-category. Dr. Parham moved to accept the recommendation. Dr. Cook seconded. Votes were taken, and the motion was carried by unanimous approval. The approved category is below.

PREFERRED AGENTS	NON-PREFERRED AGENTS
<b>HYPOGLYCEMICS, SODIUM GLUCOSE COTRANSPORTER-2 INHIBITORS</b>	
FARXIGA (dapagliflozin) JARDIANCE (empagliflozin)	INVOKANA (canagliflozin) <b>STEGLATRO (ertugliflozin)</b>

PREFERRED AGENTS	NON-PREFERRED AGENTS
<b>HYPOGLYCEMICS, SODIUM GLUCOSE COTRANSPORTER-2 INHIBITOR COMBINATIONS</b>	
SYNJARDY (empagliflozin/metformin)	GLYXAMBI (empagliflozin/linagliptin) INVOKAMET (canagliflozin/metformin) INVOKAMET XR (canagliflozin/metformin) QTERN (dapagliflozin/saxagliptin) <b>SEGLUROMET (ertugliflozin/metformin)</b> <b>STEGLUJAN (ertugliflozin/sitagliptin)</b> SYNJARDY XR (empagliflozin/metformin) XIGDUO XR (dapagliflozin/metformin)

### F. Lyrica CR

CHC recommended that Lyrica CR be made Non-Preferred in the Neuropathic Pain Agents category. Dr. Hartness moved to accept the recommendation. Dr. Ali seconded. Votes were taken, and the motion was carried by unanimous approval. The approved category is below.

PREFERRED AGENTS	NON-PREFERRED AGENTS
duloxetine gabapentin LYRICA (pregabalin) SAVELLA (milnacipran)	CYMBALTA (duloxetine) <sup>SmartPA</sup> GRALISE (gabapentin) HORIZANT (gabapentin) IRENKA (duloxetine) <b>LYRICA CR (pregabalin)</b> NEURONTIN (gabapentin)

**X. Division of Medicaid Update**

Ms. Kirby announced that Drew Synder, J.D., has been named Executive Director for the Division of Medicaid.

**XI. Other Business**

- A. Distribution of Electronic P&T Materials- The committee agreed that the CD ROM version of the P&T materials was no longer needed. These will be removed from the quarterly packets of material.

**XII. Next Meeting Date**

The next meeting of the Pharmacy & Therapeutics Committee will be held on August 14, 2018 at 10:00 a.m. in the Woolfolk Building, Conference Center East, Room 145, in Jackson, Mississippi, unless otherwise notified.

**XIII. Adjournment**

The meeting adjourned at 11:50 p.m.

DRAFT